Submitted:
04 October 2024
Posted:
07 October 2024
You are already at the latest version
Abstract
Keywords:
Background
Health Economics Evaluation Framework
Methods and Data
- EuroQoL EQ-5D-5L,
- Visual analogue scale (VAS) for overall health state (ranging between 0 ‘worst’ and 100 ‘best’ health imaginable), and
- Wellbeing scores (life satisfaction, worthwhileness, happiness and anxiousness), all measured on 0 to 10 scale, which were adapted from the Office for National Statistics, (2012).
Association of Financial Distress with QoL and Wellbeing of Informal Carers
Impact (Determinants) of Financial Distress on QoL and Wellbeing of PwPs
Limitations of the Study
Key Findings and Policy Recommendations
References
- Bhimani, R. (2014). Understanding the Burden on Caregivers of People with Parkinson’s: A Scoping Review of the Literature. Rehabilitation Research and Practice, 2014(1), 718527. [CrossRef]
- Chaudhuri, K. R., Azulay, J.-P., Odin, P., Lindvall, S., Domingos, J., Alobaidi, A., Kandukuri, P. L., Chaudhari, V. S., Parra, J. C., Yamazaki, T., Oddsdottir, J., Wright, J., & Martinez-Martin, P. (2024). Economic Burden of Parkinson’s Disease: A Multinational, Real-World, Cost-of-Illness Study. Drugs - Real World Outcomes, 11(1), 1–11. [CrossRef]
- Cholewa, J., Gorzkowska, A., Szepelawy, M., Nawrocka, A., & Cholewa, J. (2014). Influence of functional movement rehabilitation on quality of life in people with Parkinson’s disease. Journal of Physical Therapy Science, 26(9), 1329–1331. [CrossRef]
- Devlin, N. J., & Brooks, R. (2017). EQ-5D and the EuroQol Group: Past, Present and Future. Applied Health Economics and Health Policy, 15(2), 127–137. [CrossRef]
- Devlin, N., Shah, K., Feng, Y., Mulhern, B., & van Hout, B. (2016). Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England: Vol. Research Paper 16/01. Office of Health Economics.
- Dodel, R., Tinelli, M., Deuschl, G., Petersen, G., Oertel, W., & Ahmerkamp-Böhme, J. (2021). The economic benefit of timely, adequate, and adherence to Parkinson’s disease treatment: The Value of Treatment Project 2. European Journal of Neurology, 28(2), 707–716. [CrossRef]
- EuroQol Research Foundation. (2019). EQ-5D-5L User Guide [Dataset]. https://euroqol.org/publications/user-guides.
- Findley, L., Aujla, M., Bain, P. G., Baker, M., Beech, C., Bowman, C., Holmes, J., Kingdom, W. K., MacMahon, D. G., Peto, V., & Playfer, J. R. (2003). Direct economic impact of Parkinson’s disease: A research survey in the United Kingdom. Movement Disorders, 18(10), 1139–1145. [CrossRef]
- Findley, L. J. (2007). The economic impact of Parkinson’s disease. Parkinson’s Disease: From Premotor Symptoms to New Treatment Strategies, 13, S8–S12. [CrossRef]
- Findley, L. J., Wood, E., Lowin, J., Roeder, C., Bergman, A., & Schifflers, M. (2011). The economic burden of advanced Parkinson’s disease: An analysis of a UK patient dataset. Journal of Medical Economics, 14(1), 130–139. [CrossRef]
- Giles, M., Thomas, M., & Lewin, G. (2015). Ageing Intensifies the Care Needs of Adults Living with Parkinson ’s Disease and their Carers. Ageing International, 40(4), 338–352. [CrossRef]
- Gumber, A., Ramaswamy, B., Ibbotson, R., Ismail, M., Thongchundee, O., Harrop, D., Allmark, P., & Rauf, A. (2017). Economic, Social and Financial Cost of Parkinson’s on Individuals, Carers and their Families in the UK. Centre for Health and Social Care Research, Sheffield Hallam University.
- Gumber, A., Ramaswamy, B., & Thongchundee, O. (2019). Effects of Parkinson’s on employment, cost of care, and quality of life of people with condition and family caregivers in the UK: a systematic literature review. Patient Related Outcome Measures, 10(null), 321–333. [CrossRef]
- Henry, R. S., Lageman, S. K., & Perrin, P. B. (2020). The relationship between Parkinson’s disease symptoms and caregiver quality of life. Rehabilitation Psychology, 65(2), 137–144. [CrossRef]
- Janssen Daalen, J. M., Schootemeijer, S., Richard, E., Darweesh, S. K. L., & Bloem, B. R. (2022). Lifestyle Interventions for the Prevention of Parkinson Disease. Neurology, 99(7_Supplement_1), 42–51. [CrossRef]
- Marras, C., Canning, C. G., & Goldman, S. M. (2019). Environment, lifestyle, and Parkinson’s disease: Implications for prevention in the next decade. Movement Disorders, 34(6), 801–811. [CrossRef]
- McCrone, P., Allcock, L. M., & Burn, D. J. (2007). Predicting the cost of Parkinson’s disease. Movement Disorders, 22(6), 804–812. [CrossRef]
- Modugno, N., Antonini, A., Tessitore, A., Marano, P., Pontieri, F. E., Tambasco, N., Canesi, M., Fabbrini, G., Sensi, M., Quatrale, R., Solla, P., Defazio, G., Melzi, G., Gualberti, G., & Lopiano, L. (2020). Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden. Neuropsychiatric Disease and Treatment, 16(null), 2899–2912. [CrossRef]
- Moreira, R. C., Zonta, M. B., Araújo, A. P. S. de, Israel, V. L., & Teive, H. A. G. (2017). Quality of life in Parkinson’s disease patients: Progression markers of mild to moderate stages. Arquivos de Neuro-Psiquiatria, 75.
- Office for National Statistics. (2012). First Annual ONS Experimental Subjective Well-being Results. https://webarchive.nationalarchives.gov.uk/ukgwa/20160106195128/http://www.ons.gov.uk/ons/rel/wellbeing/measuring-subjective-wellbeing-in-the-uk/first-annual-ons-experimental-subjective-well-being-results/first-ons-annual-experimental-subjective-well-being-results.html.
- Parkinson’s Community Help. (2021). "The Parkinson’s Journey: Understanding Progression” – Webinar Notes. Stanford Medicine: Stanford PD Community Blog. https://parkinsonsblog.stanford.edu/2021/09/the-parkinsons-journey-understanding-progression-webinar-notes/.
- Parkinson’s UK. (2023). The cost of Parkinson’s: The financial impact of living with the condition. https://www.parkinsons.org.uk/sites/default/files/2017-07/CS2547%20Cost%20of%20Parkinson%27s%20report%202017%20-%20UK_1.pdf.
- Pontone, G. M., Dissanayaka, N., Dobkin, R. D., Mari, L., Marsh, L., Vernaleo, B. A., Weintraub, D., & Mari, Z. (2019). Integration and Extension of Specialty Mental Healthcare Services to Community Practice in Parkinson Disease. Innovations and Challenges of Training in Geriatric Mental Health, 27(7), 712–719. [CrossRef]
- Rahman, S., Griffin, H. J., Quinn, N. P., & Jahanshahi, M. (2008). Quality of life in Parkinson’s disease: The relative importance of the symptoms. Movement Disorders, 23(10), 1428–1434. [CrossRef]
- Rosqvist, K., Schrag, A., Odin, P., & the CLaSP Consortium. (2022). Caregiver Burden and Quality of Life in Late Stage Parkinson’s Disease. Brain Sciences, 12(1). [CrossRef]
- Santos-García, D., de Deus Fonticoba, T., Cores Bartolomé, C., Íñiguez Alvarado, M. C., Feal Panceiras, M. J., Suárez Castro, E., Canfield, H., Martínez Miró, C., Jesús, S., Aguilar, M., Pastor, P., Planellas, L., Cosgaya, M., García Caldentey, J., Caballol, N., Legarda, I., Hernández Vara, J., Cabo, I., López Manzanares, L., … COPPADIS Study Group. (2022). Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson’s disease patients. International Journal of Geriatric Psychiatry, 37(6). [CrossRef]
- Schrag, A., Jahanshahi, M., & Quinn, N. (2000). What contributes to quality of life in patients with Parkinson’s disease? Journal of Neurology, Neurosurgery & Psychiatry, 69(3), 308. [CrossRef]
- Tomlinson, C. L., Patel, S., Meek, C., Herd, C. P., Clarke, C. E., Stowe, R., Shah, L., Sackley, C., Deane, K. H. O., Wheatley, K., & Ives, N. (2012). Physiotherapy intervention in Parkinson’s disease: Systematic review and meta-analysis. BMJ (Clinical Research Ed.), 345, e5004. [CrossRef]
- Trend, P., Kaye, J., Gage, H., Owen, C., & Wade, D. (2002). Short-term effectiveness of intensive multidisciplinary rehabilitation for people with Parkinson’s disease and their carers. Clinical Rehabilitation, 16(7), 717–725. [CrossRef]
- Veronese, N., Nova, A., Fazia, T., Riggi, E., Yang, L., Piccio, L., Huang, B.-H., Ahmadi, M., Barbagallo, M., Notarnicola, M., Giannelli, G., De Pergola, G., Stamatakis, E., Cereda, E., Bernardinelli, L., & Fontana, L. (2024). Contribution of Nutritional, Lifestyle, and Metabolic Risk Factors to Parkinson’s Disease. Movement Disorders, 39(7), 1203–1212. [CrossRef]
- Weir, S., Samnaliev, M., Kuo, T.-C., Tierney, T. S., Walleser Autiero, S., Taylor, R. S., & Schrag, A. (2018). Short- and long-term cost and utilization of health care resources in Parkinson’s disease in the UK. Movement Disorders, 33(6), 974–981. [CrossRef]






| Respondent Characteristics | PwP | Carers | ||
|---|---|---|---|---|
| N | Percentage | N | Percentage | |
| Gender | ||||
| Male | 472 | 60.8 | 174 | 31.9 |
| Female | 298 | 38.4 | 364 | 66.7 |
| Others / Preferred not to say | 1 | 0.1 | 8 | 1.5 |
| No response | 5 | 0.6 | ||
| Marital Status | ||||
| Single / widowed / divorced separated/ other | 156 | 20.1 | 72 | 13.2 |
| Married / cohabiting | 610 | 78.6 | 465 | 85.2 |
| No response | 10 | 1.3 | 9 | 1.6 |
| Education | ||||
| All except higher education | 420 | 54.1 | 296 | 54.2 |
| Higher education | 345 | 44.5 | 344 | 43.4 |
| No response | 11 | 1.4 | 13 | 2.4 |
| Ethnic Group | ||||
| White | 714 | 92.0 | 504 | 92.3 |
| Non-white (including others) | 41 | 5.3 | 37 | 4.7 |
| No response | 21 | 2.7 | 5 | 0.9 |
| House Ownership | ||||
| Owned | 569 | 73.3 | ||
| Not owned | 102 | 13.2 | ||
| No response | 105 | 13.5 | ||
| Employment | ||||
| Working | 95 | 12.4 | 169 | 31.3 |
| Non-working (including others) | 672 | 87.6 | 339 | 62.7 |
| Income Group | ||||
| < £10000 | 114 | 21.8 | 116 | 29 |
| £10000-£19999 | 180 | 34.4 | 124 | 31 |
| £20000-£29999 | 100 | 19.1 | 59 | 14.7 |
| £30000-£39999 | 47 | 9 | 37 | 9.3 |
| £40000-£49999 | 31 | 5.9 | 15 | 3.8 |
| £50000 or more | 25 | 4.8 | 23 | 5.7 |
| Don’t know | 26 | 5.0 | 26 | 6.5 |
| Duration since Diagnosis of Parkinson’s | ||||
| Up to 2 years | 84 | 10.8 | ||
| 2.1-5 years | 155 | 20.0 | ||
| 5.1-10 years | 253 | 32.6 | ||
| 10.1-15 years | 130 | 16.8 | ||
| 15.1-20 years | 65 | 8.4 | ||
| More than 20 years | 37 | 4.8 | ||
| Not recorded | 52 | 6.7 | ||
| Sr. No. | Socioeconomic factors | QoL | VAS | Life Satisfaction | Happiness | ||||
|---|---|---|---|---|---|---|---|---|---|
| Beta Coef. | Sig. | Beta Coef. | Sig. | Beta Coef. | Sig. | Beta Coef. | Sig. | ||
| 1 | Gender (Female): Male | 0.011 | 0.77 | -0.024 | 0.53 | -0.014 | 0.71 | 0.008 | 0.84 |
| 2 | Age | 0.680 | 0.05 | 0.830 | 0.02 | 1.021 | 0.00 | 0.520 | 0.17 |
| Age Squared | -0.745 | 0.03 | -0.955 | 0.01 | -1.068 | 0.00 | -0.528 | 0.16 | |
| 3 | Marital Status (Single & WDS): Married | -0.038 | 0.33 | 0.010 | 0.80 | 0.029 | 0.47 | 0.046 | 0.27 |
| 4 | Education (Not Higher): Higher Education | 0.098 | 0.01 | 0.090 | 0.02 | 0.114 | 0.00 | 0.067 | 0.10 |
| 5 | Ethnicity (White): BME | -0.044 | 0.24 | -0.084 | 0.03 | -0.025 | 0.52 | -0.025 | 0.53 |
| 6 | House Ownership (Not Owned): Owned house | 0.118 | 0.00 | 0.123 | 0.00 | 0.112 | 0.00 | 0.140 | 0.00 |
| 7 | Occupation (Non-Working): Working | 0.072 | 0.09 | 0.073 | 0.09 | 0.115 | 0.01 | 0.078 | 0.09 |
| 8 | Income (Don’t Know): <£10,000 | -0.024 | 0.57 | -0.001 | 0.99 | -0.026 | 0.54 | -0.038 | 0.40 |
| £10,000 - £19,999 | 0.075 | 0.11 | 0.069 | 0.14 | 0.027 | 0.56 | 0.017 | 0.74 | |
| £20,000 - £29,999 | 0.072 | 0.11 | 0.033 | 0.46 | 0.020 | 0.66 | -0.009 | 0.84 | |
| £30,000 - £39,999 | 0.072 | 0.10 | 0.076 | 0.08 | -0.021 | 0.64 | -0.039 | 0.40 | |
| £40,000 - 49,999 | 0.049 | 0.23 | 0.033 | 0.42 | -0.010 | 0.81 | 0.035 | 0.42 | |
| £50,000 or more | 0.093 | 0.04 | 0.035 | 0.42 | 0.043 | 0.33 | 0.025 | 0.60 | |
| 9 | Parkinson’s duration (Not Recorded): 2-5 years | -0.036 | 0.48 | -0.027 | 0.60 | 0.065 | 0.22 | 0.043 | 0.44 |
| 5-10 years | -0.091 | 0.10 | -0.087 | 0.12 | -0.020 | 0.72 | -0.054 | 0.36 | |
| 10-15 years | -0.221 | 0.00 | -0.148 | 0.00 | -0.090 | 0.09 | -0.117 | 0.04 | |
| 15-20 years | -0.163 | 0.00 | -0.098 | 0.03 | -0.109 | 0.02 | -0.111 | 0.02 | |
| > 20 years | -0.111 | 0.01 | -0.130 | 0.00 | -0.119 | 0.01 | -0.123 | 0.01 | |
| 10 | Health services visits | -0.189 | 0.00 | -0.203 | 0.00 | -0.165 | 0.00 | -0.137 | 0.00 |
| 11 | Medication | -0.056 | 0.16 | -0.029 | 0.47 | -0.036 | 0.38 | 0.020 | 0.64 |
| 12 | Financial Burden (1st Decile): 2nd Decile (£839) | 0.004 | 0.93 | -0.018 | 0.72 | -0.002 | 0.97 | -0.009 | 0.86 |
| 3rd Decile (£2594) | -0.065 | 0.19 | -0.086 | 0.08 | -0.113 | 0.02 | -0.103 | 0.05 | |
| 4th Decile (£4840) | -0.184 | 0.00 | -0.144 | 0.00 | -0.134 | 0.01 | -0.150 | 0.00 | |
| 5th Decile (£7736) | -0.156 | 0.00 | -0.186 | 0.00 | -0.209 | 0.00 | -0.227 | 0.00 | |
| 6th Decile (£12315) | -0.178 | 0.00 | -0.128 | 0.01 | -0.178 | 0.00 | -0.154 | 0.00 | |
| 7th Decile (£18250) | -0.154 | 0.00 | -0.153 | 0.00 | -0.196 | 0.00 | -0.198 | 0.00 | |
| 8th Decile (£24686) | -0.204 | 0.00 | -0.147 | 0.00 | -0.195 | 0.00 | -0.155 | 0.00 | |
| 9th Decile (£32293) | -0.210 | 0.00 | -0.192 | 0.00 | -0.161 | 0.00 | -0.172 | 0.00 | |
| 10th Decile (£51410) | -0.198 | 0.00 | -0.204 | 0.00 | -0.192 | 0.00 | -0.181 | 0.00 | |
| 1 | Informal carers are interchangeably referred to as carers or caregivers in this paper. |
| 2 | Please refer this report for details on recruitment strategy (overall and for the booster sample) as well as other details of methodology. |
| 3 | Life satisfaction score and happiness score are jointly referred to as the psychological wellbeing scores. |
| 4 | Their study was undertaken for the United Kingdom and Germany. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).